한빛사467건

• • Athira Raveendran(전남대학교)

  • 서진희(전남대학교, Massachusetts General Hospital and Harvard Medical School)

  • 최학수(Massachusetts General Hospital and Harvard Medical School)

  • 조훈성(전남대학교)

  Lysosome-Targeted Bifunctional Therapeutics Induce Autodynamic Cancer Therapy

  • Adv. Sci. Sep 04 2024, | https://doi.org/10.1002/advs.202401424

  • 2024.09
  • 바이오·의료융합

• • 응우엔(성균관대학교)

  • 윤유석(성균관대학교)

  STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy

  • Bioact. Mater. Available online 6 September 2024; 42,345?365 | https://doi.org/10.1016/j.bioactmat.2024.09.002

  • 2024.09
  • 바이오·의료융합

• • 맹주헌(Washington University School of Medicine)

  Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells

  • Nat. Genet. 02 September 2024 | https://doi.org/10.1038/s41588-024-01880-x

  • 2024.09

• • 전희진(울산과학기술원)

  • 여미래(울산과학기술원)

  • 전준표(울산과학기술원)

  • 박성호(울산과학기술원)

  • 김은희(울산과학기술원)

  • 강세병(울산과학기술원)

  CD13-targeting and TRAIL-displaying protein nanoparticles effectively induce apoptotic cell death of acute myeloid leukemia, prolonging survival in mo

  • Nano Today Available online 4 September 2024 | https://doi.org/10.1016/j.nantod.2024.102474

  • 2024.09
  • 생명과학

• • 류지연(Harvard Medical School, Brigham and Women’s Hospital)

  • 류일환(국민대학교)

  Brain-targeted intranasal delivery of protein-based gene therapy for treatment of ischemic stroke

  • Theranostics 2024.08.12 ;14(12):4773-4786 | https://www.thno.org/v14p4773

  • 2024.08
  • 바이오·의료융합

• • 이종원(한국과학기술연구원(KIST))

  • 양유수(한국과학기술연구원(KIST))

  • 김선화(한국과학기술연구원(KIST))

  Dual-Action Protein-siRNA Conjugates for Targeted Disruption of CD47-Signal Regulatory Protein α Axis in Cancer Therapy

  • ACS Nano Aug 08 2024, | https://doi.org/10.1021/acsnano.4c06471

  • 2024.08
  • 바이오·의료융합

• • 이장순(University of Hawai'I Cancer Center)

  • 임석아(서울대학교 의과대학)

  The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overex

  • J. Exp. Clin. Cancer Res. Aug 21 2024, 43 (1) 236 | https://doi.org/10.1186/s13046-024-03143-3

  • 2024.08

• • 정예희(이화여자대학교 약학대학)

  • 신수민(이화여자대학교)

  • 서원효(이화여자대학교)

  • 이혁진(이화여자대학교 약학대학)

  Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis

  • J. Control. Release Aug 22 2024, 374 S0168-3659(24)00551-0 | https://doi.org/10.1016/j.jconrel.2024.08.012

  • 2024.08
  • 의약학

• • 이지훈(전남대학교)

  Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies

  • Cancer Treat. Rev. Aug 05 2024, 129 S0305-7372(24)00136-1 | https://doi.org/10.1016/j.ctrv.2024.102808

  • 2024.08

• • Qihang Ding(고려대학교)

  • 김종승(고려대학교)

  An ATP-responsive metal-organic framework against periodontitis via synergistic ion-interference-mediated pyroptosis

  • Natl. Sci. Rev. Aug 2024, 11 (8) nwae225 | https://doi.org/10.1093/nsr/nwae225

  • 2024.08

• • 신성영(Monash University)

  Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-selective Therapeutic Strategies for FGFR4-driven Cancers

  • Cancer Res. Aug 01 2024, | https://doi.org/10.1158/0008-5472.CAN-23-3409

  • 2024.08

• • 김태민(서울대학교병원, 서울대학교 의과대학)

  Tepotinib plus osimertinib in patients with EGFR-mutated NSCLC with MET amplification following progression on first-line osimertinib (INSIGHT 2): a m

  • Lancet Oncol. Volume 25, Issue 8 , August 2024, Pages 989-1002 | https://doi.org/10.1016/S1470-2045(24)00270-5

  • 2024.08
  • 의약학

• • 박병선(한국과학기술연구원)

  • 김택훈(한국과학기술연구원)

  Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma

  • Mol. Cancer Jul 04 2024, 23 (1) | https://doi.org/10.1186/s12943-024-02031-w

  • 2024.07
  • 생명과학

• • 나현지(고려대학교)

    Interview

  • 김종승(고려대학교)

  Bifunctional black phosphorus quantum dots platform: Delivery and remarkable immunotherapy enhancement of STING agonist

  • Biomaterials Jul 02 2024, 311 S0142-9612(24)00230-8 | https://doi.org/10.1016/j.biomaterials.2024.122696

  • 2024.07

• • 김진혁(고려대학교 의과대학, 고대구로병원)

  • 송준우(고대구로병원)

  • 김연훈(KAIST)

  • 유홍기(KAIST)

  • 박경순(중앙대학교)

  • 김진원(고려대학교 구로병원)

  Multimodal Imaging-Assisted Intravascular Theranostic Photoactivation on Atherosclerotic Plaque

  • Circ. Res. Jul 11 2024, | https://doi.org/10.1161/CIRCRESAHA.123.323970

  • 2024.07
  • 바이오·의료융합

• • 김재현(한양대학교)

    Interview

  • 김용희(한양대학교)

  Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy

  • Adv. Sci. Jul 29 2024, | https://doi.org/10.1002/advs.202403663

  • 2024.07
  • 생명과학

• • 신승원(University of California Berkeley)

  FIND-seq: high-throughput nucleic acid cytometry for rare single-cell transcriptomics

  • Nat. Protoc. Jul 22 2024, | https://doi.org/10.1038/s41596-024-01021-y

  • 2024.07

• • 서민석(서울대학교 의과대학)

  • 박지용(서울대학교 의과대학)

  • 이윤상(서울대학교 의과대학)

  • 이동수(서울대학교 의과대학)

  Optimization of micelle-encapsulated extremely small sized iron oxide nanoparticles as a T1 contrast imaging agent: biodistribution and safety profile

  • J. Nanobiotechnol. Jul 16 2024, 22 (1) | https://doi.org/10.1186/s12951-024-02699-8

  • 2024.07
  • 바이오·의료융합

• • 임성훈(연세대학교)

  • 이혜성(연세대학교)

  • 민도식(연세대학교)

  PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways

  • Exp. Mol. Med. Jul 01 2024, | https://doi.org/10.1038/s12276-024-01260-9

  • 2024.07
  • 생명과학

• • 심재혁(University of Massachusetts Chan Medical School)

  Engineering a targeted and safe bone anabolic gene therapy to treat osteoporosis in alveolar bone loss

  • Mol. Ther. Jun 26 2024, S1525-0016(24)00426-X | https://doi.org/10.1016/j.ymthe.2024.06.036

  • 2024.06
  • 의약학